Letter: therapeutic drug monitoring and inflammatory bowel disease-a call for an urgent standardization of the results.
作者信息
Ribaldone D G, Saracco G M, Astegiano M, Pellicano R
机构信息
Division of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy.
Department of General and Specialist Medicine, Città della Salute e della Scienza-Molinette Hospital, Turin, Italy.
出版信息
Aliment Pharmacol Ther. 2018 Feb;47(3):448-449. doi: 10.1111/apt.14456.
PMID:29314133
Abstract
摘要
相似文献
1
Letter: therapeutic drug monitoring and inflammatory bowel disease-a call for an urgent standardization of the results.
Aliment Pharmacol Ther. 2018 Feb;47(3):448-449. doi: 10.1111/apt.14456.
2
Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission.治疗药物监测可预测临床缓解的炎症性肠病患者英夫利昔单抗治疗降阶梯后反应丧失的情况。
Clin Res Hepatol Gastroenterol. 2016 Feb;40(1):90-8. doi: 10.1016/j.clinre.2015.05.019. Epub 2015 Jun 29.
3
Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed.
Aliment Pharmacol Ther. 2019 Mar;49(6):816-817. doi: 10.1111/apt.15081.
4
Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy.接受英夫利昔单抗治疗的炎症性肠病患者中反应性与前瞻性治疗药物监测：自我实现的预言
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1638. doi: 10.1016/j.cgh.2017.05.017. Epub 2017 May 18.
5
Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.治疗药物监测在炎症性肠病中英夫利昔单抗反应丧失的管理中比基于临床的方法更具成本效益：一项观察性多中心研究。
J Crohns Colitis. 2019 Apr 26;13(5):539-540. doi: 10.1093/ecco-jcc/jjy202.
6
Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease.治疗药物监测有助于指导接受英夫利昔单抗治疗炎症性肠病的儿童的决策过程。
Acta Paediatr. 2017 Nov;106(11):1863-1867. doi: 10.1111/apa.14008. Epub 2017 Aug 24.
7
Proactive and Reactive Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease Are Complementary, Not Mutually Exclusive.炎症性肠病生物治疗的主动和被动治疗药物监测是互补的，而非相互排斥的。
Clin Gastroenterol Hepatol. 2018 Apr;16(4):597-598. doi: 10.1016/j.cgh.2017.11.033.
8
Primary and secondary nonresponse to infliximab: mechanisms and countermeasures.英夫利昔单抗的原发性和继发性无应答：机制与对策
Expert Opin Drug Metab Toxicol. 2017 Oct;13(10):1039-1046. doi: 10.1080/17425255.2017.1377180. Epub 2017 Sep 11.
9
Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.英夫利昔单抗治疗药物监测在炎症性肠病的虚拟生物制剂临床中改变了临床决策。
Inflamm Bowel Dis. 2017 Dec;23(12):2083-2088. doi: 10.1097/MIB.0000000000001258.
10
Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.在活动性炎症性肠病中，与仅依靠临床决策相比，通过治疗药物监测来指导英夫利昔单抗剂量调整与更好的内镜检查结果相关。
Inflamm Bowel Dis. 2017 Jul;23(7):1202-1209. doi: 10.1097/MIB.0000000000001126.
Zotero 插件